Mesoblast Completes Patient Enrollment for Back Pain Therapy Trial

Overview of the Trial#

Mesoblast Limited, a biotechnology company, has announced that it has completed patient enrollment for its Phase 3 clinical trial. This trial is focused on evaluating a treatment called rexlemestrocel-L for chronic low back pain linked to degenerative disc disease. The company is valued at approximately $2.04 billion and has experienced a stock increase of 27.79% over the past year, although shares have decreased by 15.63% in 2023, currently priced at $15.22.

Trial Details#

The study will involve at least 300 patients who will be randomly assigned to receive either a single injection of rexlemestrocel-L or a placebo (a sham treatment) over a period of 12 months. The purpose of the trial is to confirm findings from an earlier study, which suggested that a single injection could lead to significant reductions in pain and lower use of opioid medications for up to three years.

The main goal of the trial is to measure the reduction in low back pain after 12 months between those receiving rexlemestrocel-L and those receiving the placebo. Additional goals include assessing improvements in daily functioning, quality of life, and the discontinuation of pain medications, including opioids.

Future Expectations#

Top-line results from the trial are anticipated in mid-2027, following the completion of patient follow-ups. If the trial yields positive results, Mesoblast plans to file for regulatory approval with the Food and Drug Administration (FDA) in the third quarter of 2027.

Rexlemestrocel-L has already received a special designation from the FDA, which could expedite its review process once the necessary application is submitted. The FDA has previously agreed on the trial's design and the primary goal of measuring pain reduction, which was successfully met in Mesoblast's earlier Phase 3 trial.

Context on Chronic Back Pain#

Chronic low back pain, often caused by inflammation and degenerative disc disease, affects over 7 million people in the United States and is responsible for about 50% of prescription opioid use in the country. Mesoblast is focused on developing cell-based therapies for inflammatory conditions, with its product Ryoncil being the first FDA-approved treatment of its kind. Recently, the company reported strong financial results, with total revenues reaching $51.3 million in the first half of fiscal year 2026, primarily driven by the success of Ryoncil.